To The Moon

$Moderna, Inc.(MRNA)$ is scheduled to report its fiscal Q2 2025 earnings on Friday, August 1, 2025, before the market opens. The company is in a transitional period as demand for its COVID-19 vaccine has significantly waned, and it is shifting its focus to other pipeline products.

This makes the upcoming report particularly important for investors seeking to understand the company's path forward. Analysts are forecasting a loss for Moderna in Q2 2025.

Earnings Per Share (EPS): The Zacks Consensus Estimate for EPS is a loss of $-2.99 per share. This is a significant improvement from the $-3.33 loss reported in Q2 2024, indicating that the company's cost-cutting measures are having an impact.

Revenue: Revenue is expected to be around $113.6 million, a substantial year-over-year decline. The company's revenue is now primarily seasonal, with the bulk of sales for its respiratory vaccines (COVID and RSV) expected in the latter half of the year.

In fiscal Q1 2025, Moderna (MRNA) reported a narrower-than-expected loss of $-2.52 per share, beating analyst forecasts. However, the company's revenue of $108 million fell short of expectations, primarily due to the seasonal nature of its business and declining demand for its COVID-19 vaccine.

The key takeaway from the guidance provided is Moderna's strategic focus on financial discipline and pipeline development to navigate its transition from a COVID-19-dependent company. Management reiterated its 2025 revenue guidance of $1.5 to $2.5 billion, with the bulk of sales expected in the second half of the year. Furthermore, the company announced a significant plan to reduce operating costs by $1.4 to $1.7 billion by 2027.

The central lesson is that Moderna's long-term value is now tied to its ability to successfully launch new products, such as its recently approved RSV vaccine (mRESVIA), and advance its other pipeline candidates while maintaining tight control over its expenses. This pivot is critical as the company works towards its goal of reaching cash flow breakeven by 2028.

Factors Influencing Performance:

Declining COVID-19 Vaccine Sales: The primary headwind for Moderna is the drastic drop in demand for its COVID-19 vaccine, which was its main revenue driver. The company has guided that most of its 2025 revenue will be concentrated in the second half of the year, driven by the fall and winter respiratory virus season.

New Product Launch (mRESVIA): Investors will be keen to see any early signs of success for Moderna's newly approved RSV vaccine, mRESVIA. While significant sales are not expected in Q2, any commentary on the launch and market competition will be crucial.

Cost Management: A key focus for the company is its financial discipline. Management has been aggressive in cutting costs, and the Q2 report will be a test of how successful these measures have been. A better-than-expected loss per share would be a strong indicator of this.

Pipeline Updates: Moderna has a robust pipeline of new products, including a combination COVID/flu vaccine, a CMV vaccine, and personalized cancer vaccines. Any updates on clinical trial data, regulatory filings, or potential launch timelines will be a major driver for the stock.

Key Metrics to Watch

Loss per Share and Revenue: The market will be watching these figures closely against analyst consensus. A smaller-than-expected loss or a revenue beat would be seen as a positive sign.

Cash and Investments: With significant cash burn from R&D, the company's cash position is a critical metric. Investors will want to see that Moderna has a healthy balance sheet to fund its long-term pipeline development.

Guidance: Any changes to the full-year 2025 revenue guidance (currently projected at $1.5 billion to $2.5 billion) and updates on cost-saving targets will be a major factor in determining the stock's direction.

Pipeline Commentary: Investors should listen for any specific details on the progress of key pipeline candidates, especially the CMV vaccine (mRNA-1647) and the personalized cancer vaccine (mRNA-4157), which are seen as critical to the company's long-term growth.

Moderna (MRNA) Price Target

Based on 20 analysts from Tiger Brokers offering 12 month price targets for Moderna in the last 3 months. The average price target is $46.90 with a high forecast of $198.00 and a low forecast of $20.00. The average price target represents a 58.66% change from the last price of $29.56.

Short-Term Trading Opportunities

Moderna's stock is known for its high volatility, with a history of significant price swings around earnings reports. This volatility can present opportunities for short-term traders.

High Volatility: The stock has a beta of 2.23, meaning it is more than twice as volatile as the broader market. This can lead to dramatic swings on earnings, which can be an opportunity for those using options strategies.

Options Trading: Given the expected volatility, options strategies like straddles or strangles could be considered, where a trader bets on a large price move in either direction. For those with a directional view, buying calls (bullish) or puts (bearish) is also an option.

Momentum Trading: A positive or negative surprise in earnings or guidance could trigger a momentum trade. A beat on the loss per share and a strong outlook on pipeline progress could cause a significant rally, while a miss or cautious guidance could lead to a sell-off.

Technical Analysis - Exponential Moving Average (EMA)

We have been seeing a downward movement where the bears are in control, though momentum remains strong, the earnings loss per share would be a huge concern on whether MRNA could show a roadmap for a comeback.

Or is there any projects in the pipeline that would be bring investors sentiment and confidence back, there is a huge possibility of volatile trading after its earnings today (01 Aug).

If MRNA could show a narrower loss per share and a better and positive outlook guidance on some of the drug pipeline, then we might see a small recovery to bring the share price at least above the 26-EMA.

Important Considerations:

Historical Context: While Moderna has a history of beating EPS estimates, its revenue has often been a concern for investors. The stock's reaction is not just about the numbers but also about the narrative and outlook provided by management.

Risk: Short-term trading in a highly volatile stock like Moderna carries significant risk. The company's financial performance is in a state of transition, and the stock price is often driven by sentiment around its pipeline, which can be unpredictable.

Summary

Moderna's upcoming Q2 2025 earnings are expected to show a loss of around $-2.99 per share, an improvement from last year's Q2. Revenue is projected to be low as the company's business has become highly seasonal, with most sales expected in the second half of the year from its respiratory vaccines.

Key metrics to watch are the company's loss per share, cash position, and any updates on new products like the mRESVIA RSV vaccine and other pipeline candidates. The stock is highly volatile, offering potential short-term trading opportunities but also significant risk.

Appreciate if you could share your thoughts in the comment section whether you think MRNA could provide a significant positive updates on its new product and pipeline.

@TigerStars @Daily_Discussion @Tiger_Earnings @TigerWire appreciate if you could feature this article so that fellow tiger would benefit from my investing and trading thoughts.

Disclaimer: The analysis and result presented does not recommend or suggest any investing in the said stock. This is purely for Analysis.